ROCURONIUM BROMIDE

Other

Brand names: Rocuronium Bromide

Intravenous

Mechanism of Action

12.1 Mechanism of Action Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.

Indications

1 INDICATIONS AND USAGE Rocuronium bromide injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation

and to provide skeletal muscle relaxation during surgery or mechanical ventilation. ( 1 )

Contraindications

• 4 CONTRAINDICATIONS Rocuronium bromide is contraindicated in patients known to have hypersensitivity (e.g.
• anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents [see Warnings and Precautions ( 5.2 )]. Hypersensitivity (e.g.
• anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Appropriate Administration and Monitoring : Use only if facilities for intubation, mechanical ventilation, oxygen therapy, and an antagonist are immediately available
2 ) Risk of Death due to Medication Errors : Accidental administration can cause death
These reactions have, in some cases (including cases with rocuronium bromide) been life threatening and fatal
3 Risk of Death due to Medication Errors Administration of rocuronium bromide results in paralysis, which may lead to respiratory arrest and death, a progression that may be more likely to occur in a patient for whom it is not intended

Known Side Effects

4 documented side effects by frequency

Low Blood Pressure

>10%

Drug Not Working

>10%

Rapid Heart Rate

0.1-1%

Rash

0.1-1%

Community Discussions

No community discussions found for ROCURONIUM BROMIDE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous